These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17642403)

  • 21. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
    Kirkwood JM; Bender C; Agarwala S; Tarhini A; Shipe-Spotloe J; Smelko B; Donnelly S; Stover L
    J Clin Oncol; 2002 Sep; 20(17):3703-18. PubMed ID: 12202672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma.
    Okereke OI
    Psychosomatics; 2002; 43(3):237-40. PubMed ID: 12075040
    [No Abstract]   [Full Text] [Related]  

  • 23. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia.
    Benelux CML Study Group
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S19-20. PubMed ID: 8769694
    [No Abstract]   [Full Text] [Related]  

  • 25. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
    Kiley KE; Gale DM
    Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lichen planus induced by interferon-alpha-2B therapy in a patient with cutaneous malignant melanoma.
    Herrera Saval A; Camacho Martínez F
    Acta Derm Venereol; 1999 Sep; 79(5):395. PubMed ID: 10494726
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
    Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
    Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
    Tarhini AA; Shipe-Spotloe J; DeMark M; Agarwala SS; Kirkwood JM
    Oncologist; 2006 May; 11(5):538-9; author reply 539-40. PubMed ID: 16720861
    [No Abstract]   [Full Text] [Related]  

  • 30. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A pilot study of low dose alpha-2b interferon in metastatic malignant melanoma with predominant subcutaneous metastases].
    Popov I; Jelić S; Kovcin V
    Srp Arh Celok Lek; 1995; 123(1-2):5-7. PubMed ID: 17974467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
    Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
    Greenberg DB; Jonasch E; Gadd MA; Ryan BF; Everett JR; Sober AJ; Mihm MA; Tanabe KK; Ott M; Haluska FG
    Cancer; 2000 Jul; 89(2):356-62. PubMed ID: 10918166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
    Sarasombath P; Sumida K; Kaku DA
    Hawaii Med J; 2002 Mar; 61(3):48, 57. PubMed ID: 11965836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex.
    Finger PT; Sedeek RW; Chin KJ
    Am J Ophthalmol; 2008 Jan; 145(1):124-129. PubMed ID: 17981257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
    Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
    Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
    Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
    J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal failure after treatment with interferon alpha 2b.
    Roeloffzen WW; Hospers GA; De Vries EG; Navis GJ
    Anticancer Res; 2002; 22(3):1929-31. PubMed ID: 12168896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.